Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1992 Jan;68(795):6–21. doi: 10.1136/pgmj.68.795.6

Bacterial challenges and evolving antibacterial drug strategy.

B Watt 1, J G Collee 1
PMCID: PMC2399299  PMID: 1561196

Full text

PDF
6

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amyes S. G. The success of plasmid-encoded resistance genes in clinical bacteria. An examination of plasmid-mediated ampicillin and trimethoprim resistance genes and their resistance mechanisms. J Med Microbiol. 1989 Feb;28(2):73–83. doi: 10.1099/00222615-28-2-73. [DOI] [PubMed] [Google Scholar]
  2. Anders B. J., Lauer B. A., Paisley J. W., Reller L. B. Double-blind placebo controlled trial of erythromycin for treatment of Campylobacter enteritis. Lancet. 1982 Jan 16;1(8264):131–132. doi: 10.1016/s0140-6736(82)90380-4. [DOI] [PubMed] [Google Scholar]
  3. Bergogne-Bérézin E., Joly-Guillou M. L., Vieu J. F. Epidemiology of nosocomial infections due to Acinetobacter calcoaceticus. J Hosp Infect. 1987 Sep;10(2):105–113. doi: 10.1016/0195-6701(87)90135-6. [DOI] [PubMed] [Google Scholar]
  4. Bornstein N., Roudier C., Fleurette J. Determination of the activity on Legionella of eight macrolides and related agents by comparative testing on three media. J Antimicrob Chemother. 1985 Jan;15(1):17–22. doi: 10.1093/jac/15.1.17. [DOI] [PubMed] [Google Scholar]
  5. Brown M. R., Costerton J. W., Gilbert P. Extrapolating to bacterial life outside the test tube. J Antimicrob Chemother. 1991 May;27(5):565–567. doi: 10.1093/jac/27.5.565. [DOI] [PubMed] [Google Scholar]
  6. Brumfitt W., Hamilton-Miller J. M. Prophylactic antibiotics for recurrent urinary tract infections. J Antimicrob Chemother. 1990 Apr;25(4):505–512. doi: 10.1093/jac/25.4.505. [DOI] [PubMed] [Google Scholar]
  7. Bush K. Beta-lactamase inhibitors from laboratory to clinic. Clin Microbiol Rev. 1988 Jan;1(1):109–123. doi: 10.1128/cmr.1.1.109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Casewell M. W. Epidemiology and control of the 'modern' methicillin-resistant Staphylococcus aureus. J Hosp Infect. 1986 Mar;7 (Suppl A):1–11. doi: 10.1016/0195-6701(86)90002-2. [DOI] [PubMed] [Google Scholar]
  9. Cavalleri B., Turconi M., Tamborini G., Occelli E., Cietto G., Pallanza R., Scotti R., Berti M., Romanó G., Parenti F. Synthesis and biological activity of some derivatives of rifamycin P. J Med Chem. 1990 May;33(5):1470–1476. doi: 10.1021/jm00167a029. [DOI] [PubMed] [Google Scholar]
  10. Chan C. C., Oppenheim B. A., Anderson H., Swindell R., Scarffe J. H. Randomized trial comparing ciprofloxacin plus netilmicin versus piperacillin plus netilmicin for empiric treatment of fever in neutropenic patients. Antimicrob Agents Chemother. 1989 Jan;33(1):87–91. doi: 10.1128/aac.33.1.87. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Clissold S. P., Todd P. A., Campoli-Richards D. M. Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1987 Mar;33(3):183–241. doi: 10.2165/00003495-198733030-00001. [DOI] [PubMed] [Google Scholar]
  12. Clyde W. A., Jr Mycoplasma pneumoniae respiratory disease symposium: summation and significance. Yale J Biol Med. 1983 Sep-Dec;56(5-6):523–527. [PMC free article] [PubMed] [Google Scholar]
  13. Cooper M. A., Andrews J. M., Ashby J. P., Matthews R. S., Wise R. In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent. J Antimicrob Chemother. 1990 Nov;26(5):667–676. doi: 10.1093/jac/26.5.667. [DOI] [PubMed] [Google Scholar]
  14. Cozzarelli N. R. DNA gyrase and the supercoiling of DNA. Science. 1980 Feb 29;207(4434):953–960. doi: 10.1126/science.6243420. [DOI] [PubMed] [Google Scholar]
  15. Dickinson J. M., Mitchison D. A. In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria. Tubercle. 1987 Sep;68(3):177–182. doi: 10.1016/0041-3879(87)90053-5. [DOI] [PubMed] [Google Scholar]
  16. Fleming D. W., Cochi S. L., Hull H. F., Helgerson S. D., Cundiff D. R., Broome C. V. Prevention of Haemophilus influenzae type b infections in day care: a public health perspective. Rev Infect Dis. 1986 Jul-Aug;8(4):568–572. doi: 10.1093/clinids/8.4.568. [DOI] [PubMed] [Google Scholar]
  17. Goodwin C. S., Marshall B. J., Blincow E. D., Wilson D. H., Blackbourn S., Phillips M. Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies. J Clin Pathol. 1988 Feb;41(2):207–210. doi: 10.1136/jcp.41.2.207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hardy D. J., Hensey D. M., Beyer J. M., Vojtko C., McDonald E. J., Fernandes P. B. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Antimicrob Agents Chemother. 1988 Nov;32(11):1710–1719. doi: 10.1128/aac.32.11.1710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Hardy D. J., Swanson R. N., Rode R. A., Marsh K., Shipkowitz N. L., Clement J. J. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. Antimicrob Agents Chemother. 1990 Jul;34(7):1407–1413. doi: 10.1128/aac.34.7.1407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Hathorn J. W., Pizzo P. A. Is there a role for monotherapy with beta-lactam antibiotics in the initial empirical management of febrile neutropenic cancer patients? J Antimicrob Chemother. 1986 Mar;17 (Suppl A):41–54. doi: 10.1093/jac/17.suppl_a.41. [DOI] [PubMed] [Google Scholar]
  21. Hedges R. W., Jacob A. E. Transposition of ampicillin resistance from RP4 to other replicons. Mol Gen Genet. 1974;132(1):31–40. doi: 10.1007/BF00268228. [DOI] [PubMed] [Google Scholar]
  22. Heifets L. B., Iseman M. D., Lindholm-Levy P. J. Combinations of rifampin or rifabutine plus ethambutol against Mycobacterium avium complex. Bactericidal synergistic, and bacteriostatic additive or synergistic effects. Am Rev Respir Dis. 1988 Mar;137(3):711–715. doi: 10.1164/ajrccm/137.3.711. [DOI] [PubMed] [Google Scholar]
  23. Heifets L. B., Lindholm-Levy P. J., Iseman M. D. Rifabutine: minimal inhibitory and bactericidal concentrations for Mycobacterium tuberculosis. Am Rev Respir Dis. 1988 Mar;137(3):719–721. doi: 10.1164/ajrccm/137.3.719. [DOI] [PubMed] [Google Scholar]
  24. Howard A. J., Williams H. M. The prevalence of antibiotic resistance in Haemophilus influenzae in Ireland. J Antimicrob Chemother. 1989 Dec;24(6):963–971. doi: 10.1093/jac/24.6.963. [DOI] [PubMed] [Google Scholar]
  25. Hughes W. T., Armstrong D., Bodey G. P., Feld R., Mandell G. L., Meyers J. D., Pizzo P. A., Schimpff S. C., Shenep J. L., Wade J. C. From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis. 1990 Mar;161(3):381–396. doi: 10.1093/infdis/161.3.381. [DOI] [PubMed] [Google Scholar]
  26. Ingham H. R., Kalbag R. M., Tharagonnet D., High A. S., Sengupta R. P., Selkon J. B. Abscesses of the frontal lobe of the brain secondary to covert dental sepsis. Lancet. 1978 Sep 2;2(8088):497–499. doi: 10.1016/s0140-6736(78)92220-1. [DOI] [PubMed] [Google Scholar]
  27. Ingham H. R., Slekon J. B., Roxby C. M. Bacteriological study of otogenic cerebral abscesses: chemotherapeutic role of metronidazole. Br Med J. 1977 Oct 15;2(6093):991–993. doi: 10.1136/bmj.2.6093.991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Kaatz G. W., Seo S. M. WIN 57273, a new fluoroquinolone with enhanced in vitro activity versus gram-positive pathogens. Antimicrob Agents Chemother. 1990 Jul;34(7):1376–1380. doi: 10.1128/aac.34.7.1376. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. King A., Boothman C., Phillips I. The in-vitro activity of PD127,391, a new quinolone. J Antimicrob Chemother. 1988 Aug;22(2):135–141. doi: 10.1093/jac/22.2.135. [DOI] [PubMed] [Google Scholar]
  30. King A., Shannon K., Phillips I. The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid. J Antimicrob Chemother. 1984 Apr;13(4):325–331. doi: 10.1093/jac/13.4.325. [DOI] [PubMed] [Google Scholar]
  31. Klastersky J., Glauser M. P., Schimpff S. C., Zinner S. H., Gaya H. Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients. Antimicrob Agents Chemother. 1986 Feb;29(2):263–270. doi: 10.1128/aac.29.2.263. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Kuck N. A., Jacobus N. V., Petersen P. J., Weiss W. J., Testa R. T. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam. Antimicrob Agents Chemother. 1989 Nov;33(11):1964–1969. doi: 10.1128/aac.33.11.1964. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Ledingham I. M., Alcock S. R., Eastaway A. T., McDonald J. C., McKay I. C., Ramsay G. Triple regimen of selective decontamination of the digestive tract, systemic cefotaxime, and microbiological surveillance for prevention of acquired infection in intensive care. Lancet. 1988 Apr 9;1(8589):785–790. doi: 10.1016/s0140-6736(88)91656-x. [DOI] [PubMed] [Google Scholar]
  34. Leigh D. A., Tait S., Walsh B. Antibacterial activity of lomefloxacin. J Antimicrob Chemother. 1991 May;27(5):589–598. doi: 10.1093/jac/27.5.589. [DOI] [PubMed] [Google Scholar]
  35. Lewin C. S., Allen R. A., Amyes S. G. Potential mechanisms of resistance to the modern fluorinated 4-quinolones. J Med Microbiol. 1990 Mar;31(3):153–162. doi: 10.1099/00222615-31-3-153. [DOI] [PubMed] [Google Scholar]
  36. Livermore D. M., Wood M. J. Mechanisms and clinical significance of resistance to new beta-lactam antibiotics. Br J Hosp Med. 1990 Oct;44(4):252-8, 261-3. [PubMed] [Google Scholar]
  37. Lovering A. M., Bywater M. J., Holt H. A., Champion H. M., Reeves D. S. Resistance of bacterial pathogens to four aminoglycosides and six other antibacterials and prevalence of aminoglycoside modifying enzymes, in 20 UK centres. J Antimicrob Chemother. 1988 Dec;22(6):823–839. doi: 10.1093/jac/22.6.823. [DOI] [PubMed] [Google Scholar]
  38. Macfarlane J. T., Finch R. G., Ward M. J., Macrae A. D. Hospital study of adult community-acquired pneumonia. Lancet. 1982 Jul 31;2(8292):255–258. doi: 10.1016/s0140-6736(82)90334-8. [DOI] [PubMed] [Google Scholar]
  39. Malmborg A. S. The renaissance of erythromycin. J Antimicrob Chemother. 1986 Sep;18(3):293–296. doi: 10.1093/jac/18.3.293. [DOI] [PubMed] [Google Scholar]
  40. Martin J. R., Johnson P., Miller M. F. Uptake, accumulation, and egress of erythromycin by tissue culture cells of human origin. Antimicrob Agents Chemother. 1985 Mar;27(3):314–319. doi: 10.1128/aac.27.3.314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Mattie H., Craig W. A., Pechère J. C. Determinants of efficacy and toxicity of aminoglycosides. J Antimicrob Chemother. 1989 Sep;24(3):281–293. doi: 10.1093/jac/24.3.281. [DOI] [PubMed] [Google Scholar]
  42. Miller M. F., Martin J. R., Johnson P., Ulrich J. T., Rdzok E. J., Billing P. Erythromycin uptake and accumulation by human polymorphonuclear leukocytes and efficacy of erythromycin in killing ingested Legionella pneumophila. J Infect Dis. 1984 May;149(5):714–718. doi: 10.1093/infdis/149.5.714. [DOI] [PubMed] [Google Scholar]
  43. Palmer S. R. Psittacosis in man - recent developments in the UK: a review. J R Soc Med. 1982 Apr;75(4):262–267. doi: 10.1177/014107688207500412. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Pearce J. M. Pelvic inflammatory disease. BMJ. 1990 Apr 28;300(6732):1090–1091. doi: 10.1136/bmj.300.6732.1090. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Piercy E. A., Barbaro D., Luby J. P., Mackowiak P. A. Ciprofloxacin for methicillin-resistant Staphylococcus aureus infections. Antimicrob Agents Chemother. 1989 Jan;33(1):128–130. doi: 10.1128/aac.33.1.128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Pizzo P. A. After empiric therapy: what to do until the granulocyte comes back. Rev Infect Dis. 1987 Jan-Feb;9(1):214–219. doi: 10.1093/clinids/9.1.214. [DOI] [PubMed] [Google Scholar]
  47. Pollock A. V. Surgical prophylaxis--the emerging picture. Lancet. 1988 Jan 30;1(8579):225–230. doi: 10.1016/s0140-6736(88)91074-4. [DOI] [PubMed] [Google Scholar]
  48. Powell M., Koutsia-Carouzou C., Voutsinas D., Seymour A., Williams J. D. Resistance of clinical isolates of Haemophilus influenzae in United Kingdom 1986. Br Med J (Clin Res Ed) 1987 Jul 18;295(6591):176–179. doi: 10.1136/bmj.295.6591.176. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Rolinson G. N. Beta-lactam antibiotics. J Antimicrob Chemother. 1986 Jan;17(1):5–36. doi: 10.1093/jac/17.1.5. [DOI] [PubMed] [Google Scholar]
  50. Saito H., Sato K., Tomioka H. Comparative in vitro and in vivo activity of rifabutin and rifampicin against Mycobacterium avium complex. Tubercle. 1988 Sep;69(3):187–192. doi: 10.1016/0041-3879(88)90020-7. [DOI] [PubMed] [Google Scholar]
  51. Sanders C. C., Sanders W. E., Jr, Goering R. V. Overview of preclinical studies with ciprofloxacin. Am J Med. 1987 Apr 27;82(4A):2–11. [PubMed] [Google Scholar]
  52. Sanford J. P. Legionnaires' disease--the first thousand days. N Engl J Med. 1979 Mar 22;300(12):654–656. doi: 10.1056/NEJM197903223001205. [DOI] [PubMed] [Google Scholar]
  53. Smyth E. G., Pallett A. P. Clinicians' guide to antibiotics. Chloramphenicol. Br J Hosp Med. 1988 May;39(5):424–428. [PubMed] [Google Scholar]
  54. Stevens J. D., Mission G. P. Ophthalmic use of chloramphenicol. Lancet. 1987 Dec 19;2(8573):1456–1456. doi: 10.1016/s0140-6736(87)91148-2. [DOI] [PubMed] [Google Scholar]
  55. Stoutenbeek C. P., van Saene H. K., Miranda D. R., Zandstra D. F., Binnendijk B. The prevention of superinfection in multiple trauma patients. J Antimicrob Chemother. 1984 Sep;14 (Suppl B):203–211. doi: 10.1093/jac/14.suppl_b.203. [DOI] [PubMed] [Google Scholar]
  56. Vaneechoutte M., Verschraegen G., Claeys G., Weise B., Van den Abeele A. M. Respiratory tract carrier rates of Moraxella (Branhamella) catarrhalis in adults and children and interpretation of the isolation of M. catarrhalis from sputum. J Clin Microbiol. 1990 Dec;28(12):2674–2680. doi: 10.1128/jcm.28.12.2674-2680.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Wall R. A. The chemoprophylaxis of meningococcal infection. J Antimicrob Chemother. 1988 Jun;21(6):698–700. doi: 10.1093/jac/21.6.698. [DOI] [PubMed] [Google Scholar]
  58. Watt B., Brown F. V. Is ciprofloxacin active against clinically important anaerobes? J Antimicrob Chemother. 1986 May;17(5):605–613. doi: 10.1093/jac/17.5.605. [DOI] [PubMed] [Google Scholar]
  59. Welsby P. D., Golledge C. L. Meningococcal meningitis. BMJ. 1990 May 5;300(6733):1150–1151. doi: 10.1136/bmj.300.6733.1150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Wilcox M. H., Finch R. G., Smith D. G., Williams P., Denyer S. P. Effects of carbon dioxide and sub-lethal levels of antibiotics on adherence of coagulase-negative staphylococci to polystyrene and silicone rubber. J Antimicrob Chemother. 1991 May;27(5):577–587. doi: 10.1093/jac/27.5.577. [DOI] [PubMed] [Google Scholar]
  61. Wolfson J. S., Hooper D. C. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother. 1985 Oct;28(4):581–586. doi: 10.1128/aac.28.4.581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Woodhead M. A., Macfarlane J. T. Legionnaires' disease: a review of 79 community acquired cases in Nottingham. Thorax. 1986 Aug;41(8):635–640. doi: 10.1136/thx.41.8.635. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Wosornu D., MacIntyre D., Watt B. An outbreak of isoniazid resistant tuberculosis in Glasgow 1981-1988. Respir Med. 1990 Sep;84(5):361–364. doi: 10.1016/s0954-6111(08)80069-8. [DOI] [PubMed] [Google Scholar]
  64. Yajko D. M., Sanders C. A., Nassos P. S., Hadley W. K. In vitro susceptibility of Mycobacterium avium complex to the new fluoroquinolone sparfloxacin (CI-978; AT-4140) and comparison with ciprofloxacin. Antimicrob Agents Chemother. 1990 Dec;34(12):2442–2444. doi: 10.1128/aac.34.12.2442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Young L. S., Berlin O. G., Inderlied C. B. Activity of ciprofloxacin and other fluorinated quinolones against mycobacteria. Am J Med. 1987 Apr 27;82(4A):23–26. [PubMed] [Google Scholar]
  66. Young L. S. Mycobacterium avium complex infection. J Infect Dis. 1988 May;157(5):863–867. doi: 10.1093/infdis/157.5.863. [DOI] [PubMed] [Google Scholar]
  67. de Louvois J., Gortavai P., Hurley R. Bacteriology of abscesses of the central nervous system: a multicentre prospective study. Br Med J. 1977 Oct 15;2(6093):981–984. doi: 10.1136/bmj.2.6093.981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. de Louvois J., Gortvai P., Hurley R. Antibiotic treatment of abscesses of the central nervous system. Br Med J. 1977 Oct 15;2(6093):985–987. doi: 10.1136/bmj.2.6093.985. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES